A new study performed by Boston Medical Center (BMC) and faculty at the Boston University School of Medicine shows that urine drug testing can be a useful tool to treat patients with opioid use disorder in a primary care setting. The analysis revealed that patients are less likely to disclose drug use earlier in treatment, and although the study was not able to identify reasons for this, the authors believe that it may be related to fear of discharge from a treatment program and stigma related to relapse. Published in Drug and Alcohol Dependence, the study indicates the need to develop interventions for patients who have positive urine drug tests in order to keep them engaged in care.
Office-based addiction treatment has become a key strategy in combating the opioid epidemic in the United States, where patients get treatment for their disease in a primary care setting with close monitoring during their recovery. However, one of the questions in the current practice of is how best to monitor for illicit substance use, especially when patients do not report it. There has also been a lack of data regarding how frequently patients in these programs report substance use compared to finding a positive result by urine drug testing (UDT).